J&J Makes Its Biggest Bet Yet On Antibody-Drug Conjugates With Ambrx Buyout

 
• By Alaric DeArment

CEO Joaquin Duato told the J.P. Morgan Healthcare Conference that the drug maker hopes the $2bn acquisition can make one of its lead candidates, ARX517, the first PSMA-directed ADC for prostate cancer.

J&J CEO Joaquin Duato spoke about the company's acquisition of Ambrx at the J.P. Morgan Healthcare Conference • Source: Shutterstock

More from Deals

More from Business